U.S. Markets closed

Arbutus: Potential Near-Term Catalysts and Pipeline Overview

NEW YORK, NY / ACCESSWIRE / September 12, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Arbutus Biopharma Corporation (ABUS), a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection.

Per the Hepatitis B foundation, there are an estimated 257 million people worldwide who are chronically infected with the Hepatitis B virus. More than 2 million Americans are infected with the virus and the Hepatitis B market is expected to reach $3.5 billion by 2021.

The company also announced that it will host a live, informational webinar titled, "LNP: Delivering mRNA Therapeutics to the Clinic", on September 12, 2017. As per management, progress continues to be made in the development of mRNA as potential therapeutics to treat human disease. However, successful delivery of mRNA into target cells still constitutes the primary hurdle in the clinical development of these new therapies.

The company is expected to provide greater insights into the broad applicability of mRNA therapeutics, and outline the inherent hurdles nucleic acid therapeutics face with targeted drug delivery and address what is being done to overcome these unique challenges.

Read about the potential near-term catalysts for Arbutus in our full report READ MORE

Copy and paste to your browser may be required to view the report – http://bit.ly/2xrUD5K-Analyst-ABUS

The company is in the process developing a combination of products and these combinations will include a single product from its pipeline combined with approved agents. Furthermore, the company also communicated that ARB-1740 was relatively more potent than ARB-1467 in preclinical studies and has the potential to be effective at lower clinical doses than ARB-1467.

Arbutus's preclinical research continues to add new agents to expand this strategy and generate great value as evidenced by its recent drug candidate nominations AB-506, a next-generation capsid inhibitor and AB-452, a novel and unique HBV RNA destabilizer, both of which target multiple aspects of the HBV life cycle.

Arbutus drug pipeline and details of the upcoming FDA review available here READ MORE

Copy and paste to your browser may be required to view the report – http://bit.ly/2xrUD5K-Analyst-ABUS


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



SOURCE: Traders News Source